← Reports

R&D Investment and Output, Korea's Listed Healthcare Sector — H1 2026

R&D, financials, headcount and export sales of 252 listed companies joined to approvals, trials, publications and patents · computed 2026-10-07 · published half-yearly

This report joins the R&D spend disclosed by Korea's listed healthcare companies to the approvals, trials, publications and patents the same companies produced over the same period. Tallies of R&D spend say how much was invested; what it turned into can only be counted once five sources are joined at the company level. Every figure is a tally of primary filings and regulatory or bibliographic records; methods and limitations are disclosed below. Free to quote and reuse with attribution to Medical AI Alliance (MAA), under CC BY 4.0.

First edition 2026-09-24 · Full edition 2026-10-07 · Measured 2026-10-07 · Medical AI Alliance

Key findings

KRW 3.08tn
R&D spend, H1 2026
252 companies
+15.3%
Year on year
204 comparable · 115 up · 89 down
10.7%
R&D as % of revenue
244 companies · company median 9.4%
32.5%
Share of R&D at loss-makers
114 of 244 companies
15.8%
Capitalised share of R&D
188 companies with reconciled accounting
27.7%
Export share of sales
Sales table, 137 companies · 38.5% incl. overseas subsidiaries
  1. 252 listed healthcare companies spent KRW 3.08tn on R&D in H1 2026, +15.3% year on year on a like-for-like basis.
  2. A few companies drove the rise. The ten largest increases made 84% of the net increase, while 89 companies cut spending.
  3. 32.5% of R&D is spent by loss-making companies. 76 of the 114 loss-makers decided equity or bond issues in 2024–2025, worth 1.4x their R&D over the same years.
  4. Biotech spends 30% of revenue on R&D at a -15% operating margin; pharma & CDMO 8% and 15%.
  5. 17 companies disclosed 25 out-licensing deals. The 15 with a KRW value total KRW 15.26tn; upfronts: KRW 522.9bn (17 deals).
  6. 34 companies run phase 3 trials. 2024–2025: 43 Korean and 52 global phase 3 starts; 224 bioequivalence studies counted separately.
  7. Companies with reconciled accounting capitalise 15.8% of R&D. Exports are 27.7% of sales on the sales-table basis (38.5% including overseas subsidiaries' sales).
  8. Over 2024–2025, 260 companies spent KRW 11.14tn on R&D; the same period produced 1,874 approvals, 284 Korean trial authorisations and 1,081 papers. Among the Korean reports we reviewed, the first to join spend and output company by company.

At a glance

What this report adds

  1. It joins money to output, company by company. Two years of R&D at 260 companies sit next to the same companies' approvals, trials by phase, papers, patents and licensing deals. The Korean reports we reviewed count spending only.
  2. It shows where the money comes from. R&D at 114 loss-making companies is set against 353 equity and bond issue decisions on the same company axis.
  3. It names companies and publishes the full data. An appendix and CSV for all 252 companies let anyone recompute the figures.
  4. It shows its checks. Ratios are recomputed with the filing form's formula; the 11 companies whose self-reported ratio differs, and every correction, are disclosed. Key figures are cross-checked through two independent paths.
  5. It is fast and regular. August half-year filings are analysed in October; medical AI is tracked as its own sector.
  6. It counts licensing and pipelines from the filings. 34 companies with phase 3 trials and 25 out-licensing deals, each read from the source filing and checked against a verbatim quote.

About this survey

Coverage — 252 Korean listed healthcare, biotech and medical-device companies whose H1 2026 R&D spend passed our cross-check. 19 companies whose main business is not healthcare and 10 parents that consolidate listed subsidiaries (nine holding companies and SK Chemicals) are excluded. It covers every index company whose R&D passed our cross-check; those that did not are reported in the method section.

Reference date — 30 June 2026. Income and R&D are January–June totals; headcount is at period end. Prior-year figures are those restated in the 2026 filings.

Breakdowns — five MAA index sectors, and company size as each company declares it in its periodic filing (large 12 · mid-sized 88 · SME 152). Definitions are in the method section.

Interests — MAA member companies are among those covered; membership has no bearing on any figure or ranking. Every number is computed from public filings and databases under the same rules.

Prepared by the Medical AI Alliance (MAA), computed 2026-10-07. The table shows how many companies each item covers; counts differ because only cross-checked values are used.

ItemSourceCompanies (n)
R&D spend, change, trendR&D expense table in half-year and annual filings252
R&D accounting (expensed / capitalised)Accounting lines of the same table188
R&D by natureNature lines of the same table134
Revenue, operating profitDART financial API (KRW filers)244
Domestic vs export salesSales table, else regional note172
EmployeesDART employee status (parent)242
Company sizeSME / mid-sized status as self-declared252
Approvals, trials, papers, patents (2 years)MFDS, FDA, ClinicalTrials.gov, PubMed, KIPRIS260
I

I. R&D investment

How much, where it grew, how it was accounted for

KRW 3.08tnH1 total+15.3%YoY15.8%Capitalised
  • Pharma & CDMO (98 companies) spent 55% of R&D
  • Up 15.3% across 204 comparable companies, yet 89 cut spending
  • The ten largest increases made up 84% of the net rise

I-1. H1 2026 R&D spend — sector × size

  1. H1 2026 R&D spend across 252 companies was KRW 3.08tn.
  2. By sector, Pharma & CDMO (98 companies) accounted for 55.3%.
  3. By size, mid-sized companies (88) spent the most at 51.4%; the 12 large companies spent 25.7%.
Figure I-1
Pharma & CDMO spends 55% of R&D; mid-sized companies 51%
H1 2026 R&D spend by sector and company size, KRW bn · 252 companies
Pharma & CDMO
1,704.5
Biotech & drug discovery
985.8
Medical devices
335.5
Medical AI
46.3
Healthcare infrastructure
11.9
LargeMid-sizedSME
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
Sector \ size (KRW bn)LargeMid-sizedSMEAll
Pharma & CDMO518.3 (8)1,106.2 (52)80.1 (38)1,704.5 (98)
Biotech & drug discovery275.5 (4)232.6 (10)477.7 (54)985.8 (68)
Medical devices—240.0 (24)95.5 (43)335.5 (67)
Medical AI——46.3 (12)46.3 (12)
Healthcare infrastructure—— (2)5.3 (5)11.9 (7)
All793.8 (12)1,585.5 (88)704.8 (152)3,084.1 (252)

Company counts in brackets. Cells with fewer than three companies are shown as "—".

I-2. Year-on-year change

  1. Among the 204 companies comparable year on year, R&D spend rose 15.3%: 115 increased and 89 decreased.
  2. Growth was fastest in Biotech & drug discovery (+26.4%) and slowest in Medical AI (+0.7%), among sectors with ten or more companies.
  3. Aggregate growth follows the largest spenders; read it alongside the count of companies that rose and fell.
Figure I-2a
Biotech & drug discovery led with +26.4%
Year-on-year change in R&D spend, same companies · by sector
Biotech & drug discovery
+26.4%n=57
Pharma & CDMO
+11.6%n=83
Medical devices
+6.0%n=47
Healthcare infrastructure
+3.1%n=7
Medical AI
+0.7%n=10
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
Figure I-2b
By size, large companies grew most (+25.9%)
Same basis, by company size
Large
+25.9%n=10
Mid-sized
+12.4%n=75
SME
+13.0%n=119
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
Sector \ sizeLargeMid-sizedSMEAll
Pharma & CDMO+23.1% (6)+8.6% (43)+8.7% (34)+11.6% (83)
Biotech & drug discovery+29.4% (4)+33.6% (9)+20.8% (44)+26.4% (57)
Medical devices—+12.5% (21)-12.8% (26)+6.0% (47)
Medical AI——+0.7% (10)+0.7% (10)
Healthcare infrastructure—— (2)-12.7% (5)+3.1% (7)
All+25.9% (10)+12.4% (75)+13.0% (119)+15.3% (204)

Growth is computed on the same companies' totals; brackets show companies compared. Companies whose consolidation scope changed (e.g. the Samsung Biologics demerger) are excluded.

I-3. Trend

  1. The same 203 companies with values in all five periods.
  2. Annual R&D went from KRW 4.32tn in 2023 to KRW 5.04tn in 2025 (+16.5%).
  3. Half-year on half-year: +15.3%.
Figure I-3
In two years Medical AI grew 57%; Pharma & CDMO +8%
Annual R&D index (2023 = 100), same 203 companies · sectors with 10+ companies
90110130150170202320242025Pharma & CDMO 2023 100.0Pharma & CDMO 2024 102.7Pharma & CDMO 2025 108.5Biotech & drug discovery 2023 100.0Biotech & drug discovery 2024 108.4Biotech & drug discovery 2025 132.6Medical devices 2023 100.0Medical devices 2024 113.9Medical devices 2025 116.0Medical AI 2023 100.0Medical AI 2024 128.7Medical AI 2025 157.2All 2023 100.0All 2024 105.9All 2025 116.5Medical AI (157)Biotech & drug discovery (133)All (117)Medical devices (116)Pharma & CDMO (108)
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
Sector (KRW bn)FY2023FY2024FY2025H1 2025H1 2026
Pharma & CDMO2,551.82,621.82,768.11,312.31,464.5
Biotech & drug discovery1,207.51,308.71,600.7725.1916.4
Medical devices477.4543.6553.8263.4279.1
Medical AI58.274.991.440.540.8
Healthcare infrastructure27.127.822.411.511.9
All4,321.94,576.95,036.42,352.92,712.7

I-4. The twenty largest spenders

  1. The top twenty spent KRW 1.79tn, 58.2% of the total.
  2. Celltrion, Inc. leads with KRW 284.3bn.
  3. Ratios to revenue vary with stage: large-revenue companies spend more in absolute terms at lower ratios.
Figure I-4
Top twenty spend 58%; LigaChem Biosciences Inc. up from #8 to #2
Top 20 by H1 2026 R&D, KRW bn · prior-half rank in brackets · right: % of revenue
1.Celltrion, Inc. (1)
284.3–
2.LigaChem Biosciences Inc. (8)
137.1▲6
3.Hanmi Pharm. Co., Ltd. (4)
125.5▲1
4.SK Bioscience Co.,Ltd (9)
122.4▲5
5.YUHAN CORPORATION (2)
122.2▼3
6.DAEWOONG PHARMA (3)
115.7▼3
7.Chong Kun Dang Pharmaceutical Corp. (5)
113.5▼2
8.SAMSUNG EPIS HOLDINGS Co., Ltd. (—)
106.0—
9.SK biopharmaceuticals Co., Ltd. (7)
97.3▼2
10.GC Biopharma Corp. (6)
85.9▼4
11.SAMSUNG BIOLOGICS CO.,LTD. (—)
81.9—
12.DONG-A ST CO.,LTD (10)
55.2▼2
13.ABL Bio Inc. (12)
48.8▼1
14.Kolon TissueGene, Inc. (11)
48.0▼3
15.MEDIPOSTCO.,LTD. (16)
44.0▲1
16.JW PHARMACEUTICAL (13)
43.1▼3
17.SD BIOSENSOR INC. (15)
42.9▼2
18.HK inno.N Corporation (14)
42.6▼4
19.Voronoi, Inc. (24)
41.7▲5
20.JEIL PHARMACEUTICAL CO.,LTD (25)
35.9▲5
Prior ranks among comparable companies; "—": not comparable (e.g. demerger) · Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
RankCompanySectorSizeH1 2026 (KRW bn)YoY% of revenue
1Celltrion, Inc.Pharma & CDMOLarge284.3+23.8%11.2%
2LigaChem Biosciences Inc.Biotech & drug discoveryMid-sized137.1+77.4%331.1%
3Hanmi Pharm. Co., Ltd.Pharma & CDMOMid-sized125.5+18.2%14.6%
4SK Bioscience Co.,LtdBiotech & drug discoveryLarge122.4+80.0%37.7%
5YUHAN CORPORATIONPharma & CDMOMid-sized122.2+13.8%10.5%
6DAEWOONG PHARMAPharma & CDMOMid-sized115.7+8.5%15.7%
7Chong Kun Dang Pharmaceutical Corp.Pharma & CDMOMid-sized113.5+36.6%12.3%
8SAMSUNG EPIS HOLDINGS Co., Ltd.Pharma & CDMOLarge106.0—12.5%
9SK biopharmaceuticals Co., Ltd.Biotech & drug discoveryLarge97.3+19.2%20.5%
10GC Biopharma Corp.Pharma & CDMOMid-sized85.9+3.8%10.0%
11SAMSUNG BIOLOGICS CO.,LTD.Pharma & CDMOLarge81.9—3.2%
12DONG-A ST CO.,LTDPharma & CDMOMid-sized55.2-8.5%12.9%
13ABL Bio Inc.Biotech & drug discoverySME48.8-8.9%148.6%
14Kolon TissueGene, Inc.Biotech & drug discoveryLarge48.0-11.4%—
15MEDIPOSTCO.,LTD.Biotech & drug discoverySME44.0+28.3%115.1%
16JW PHARMACEUTICALPharma & CDMOMid-sized43.1-11.5%10.2%
17SD BIOSENSOR INC.Medical devicesMid-sized42.9+18.8%11.3%
18HK inno.N CorporationPharma & CDMOMid-sized42.6+12.8%8.1%
19Voronoi, Inc.Biotech & drug discoverySME41.7+95.4%—
20JEIL PHARMACEUTICAL CO.,LTDPharma & CDMOMid-sized35.9+68.4%13.0%

I-5. Largest increases and decreases

  1. Net increase across comparable companies: KRW 360.0bn.
  2. The ten largest increases sum to KRW 301.4bn, 83.7% of the net rise.
Figure I-5
Ten companies made 84% of the KRW 360.0bn net rise
Ten largest increases and decreases, KRW bn
LigaChem Biosciences Inc.
+59.8
Celltrion, Inc.
+54.6
SK Bioscience Co.,Ltd
+54.4
Chong Kun Dang Pharmaceutical Corp.
+30.4
Voronoi, Inc.
+20.4
Hanmi Pharm. Co., Ltd.
+19.3
SAM CHUN DANG PHARM CO. LTD
+17.3
SK biopharmaceuticals Co., Ltd.
+15.7
YUHAN CORPORATION
+14.8
JEIL PHARMACEUTICAL CO.,LTD
+14.6
HANALL BIOPHARMA CO.,LTD
−4.1
Lunit Inc.
−4.6
Cellid Co., Ltd.
−4.7
ABL Bio Inc.
−4.8
DONG-A ST CO.,LTD
−5.1
JW PHARMACEUTICAL
−5.6
JETEMA Co.,Ltd.
−6.0
Kolon TissueGene, Inc.
−6.2
SEEGENE, INC.
−7.4
Aprogen, Inc
−20.4
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
RankCompanyH1 2025 (KRW bn)H1 2026 (KRW bn)Change (KRW bn)
1LigaChem Biosciences Inc.77.3137.1+59.8
2Celltrion, Inc.229.7284.3+54.6
3SK Bioscience Co.,Ltd68.0122.4+54.4
4Chong Kun Dang Pharmaceutical Corp.83.1113.5+30.4
5Voronoi, Inc.21.441.7+20.4
6Hanmi Pharm. Co., Ltd.106.2125.5+19.3
7SAM CHUN DANG PHARM CO. LTD4.421.7+17.3
8SK biopharmaceuticals Co., Ltd.81.697.3+15.7
9YUHAN CORPORATION107.3122.2+14.8
10JEIL PHARMACEUTICAL CO.,LTD21.335.9+14.6
RankCompanyH1 2025 (KRW bn)H1 2026 (KRW bn)Change (KRW bn)
1Aprogen, Inc30.39.9−20.4
2SEEGENE, INC.33.626.1−7.4
3Kolon TissueGene, Inc.54.248.0−6.2
4JETEMA Co.,Ltd.11.35.3−6.0
5JW PHARMACEUTICAL48.843.1−5.6
6DONG-A ST CO.,LTD60.455.2−5.1
7ABL Bio Inc.53.548.8−4.8
8Cellid Co., Ltd.8.43.7−4.7
9Lunit Inc.19.014.4−4.6
10HANALL BIOPHARMA CO.,LTD18.414.3−4.1

I-6. How R&D is accounted for, and what it buys

  1. Among the 188 companies whose accounting lines reconcile (86% of R&D), 15.8% was capitalised as development cost.
  2. Capitalisation defers cost, so the same spend weighs less on current profit.
  3. Government grants totalled KRW 57.3bn.
Figure I-6a
Pharma & CDMO capitalises 20% of R&D
Accounting split, 188 reconciling companies (86% of R&D)
Pharma & CDMO
80%20%
Biotech & drug discovery
88%12%
Medical devices
99%
Medical AI
96%
All
84%16%
ExpensedCapitalised
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
Figure I-6b
Personnel and contracted services are about 26% each
By nature, 134 companies (56% of R&D)
Pharma & CDMO
25%29%16%24%
Biotech & drug discovery
19%24%18%36%
Medical devices
46%12%27%
All
26%26%16%27%
PersonnelContracted servicesMaterialsDepreciationOther
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
Capitalised shareLargeMid-sizedSMEAll
Pharma & CDMO38.7% (6)11.5% (44)4.0% (27)19.9% (77)
Biotech & drug discovery42.8% (3)4.3% (8)4.6% (45)12.5% (56)
Medical devices—0.1% (18)2.0% (32)0.5% (50)
Medical AI——4.5% (3)4.5% (3)
Healthcare infrastructure—— (1)— (1)— (2)
All39.7% (9)9.0% (71)4.3% (108)15.8% (188)

Only companies whose lines sum to the total (±1%) are included. Grants are not re-allocated.

II

II. Profitability and funding

R&D against revenue and profit, export sales, and where the money comes from

10.7%R&D / revenue114Loss-making27.7%Export share
  • 32% of R&D is spent by 114 loss-makers
  • Biotech & drug discovery has the highest R&D intensity (30.4%)
  • Exports are 27.7% of sales on the sales-table basis (38.5% incl. overseas subsidiaries)

II-1. Revenue, operating profit and R&D intensity

  1. The 244 companies with financials had H1 revenue of KRW 27.96tn (+13.0% YoY), an operating margin of 10.8% and R&D equal to 10.7% of revenue.
  2. Biotech & drug discovery has both the highest R&D intensity (30.4%) and the lowest operating margin (-14.9%).
  3. SMEs: R&D intensity 19.3%, operating margin -11.3%; large companies: 9.8% and 30.7%.
Against the world — in the 2024 EU Industrial R&D Investment Scoreboard (the world's top 2,000 R&D investors), the 437 health-sector companies spent 13.5% of 2023 sales on R&D, EUR 590.6m per company (about KRW 841.5bn a year at that report's rate). The 252 companies here spent 10.7% of H1 2026 revenue. Definitions differ: own-funded, annual, global leaders versus pre-grant, half-year, all Korean listed companies (DOI 10.2760/0775231, Table 10).
Figure II-1
Biotech & drug discovery spends 30% of revenue on R&D at a -15% margin
Three measures side by side by sector, each on its own scale · half-year totals
R&D / revenue
Pharma & CDMO
8.4%
Biotech & drug discovery
30.4%
Medical devices
8.4%
Medical AI
18.1%
Healthcare infrastructure
2.2%
Operating margin
Pharma & CDMO
+15.1%
Biotech & drug discovery
-14.9%
Medical devices
+10.7%
Medical AI
-11.4%
Healthcare infrastructure
+4.2%
Share loss-making
Pharma & CDMO
33%
Biotech & drug discovery
74%
Medical devices
39%
Medical AI
60%
Healthcare infrastructure
29%
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
SectorCompanies (n)Revenue (KRW bn)Revenue YoYOperating marginR&D / revenueLoss-making (n)
Pharma & CDMO9620,248.7+13.6%15.1%8.4%32
Biotech & drug discovery652,954.9+12.0%-14.9%30.4%48
Medical devices663,966.4+10.8%10.7%8.4%26
Medical AI10239.2+37.9%-11.4%18.1%6
Healthcare infrastructure7548.8+5.0%4.2%2.2%2
All24427,958.0+13.0%10.8%10.7%114
SizeCompanies (n)Revenue (KRW bn)Revenue YoYOperating marginR&D / revenueLoss-making (n)
Large117,634.0+30.2%30.7%9.8%3
Mid-sized8816,944.5+6.3%6.3%9.4%23
SME1453,379.5+19.0%-11.3%19.3%88
All24427,958.0+13.0%10.8%10.7%114

Ratios are computed on totals, so large companies weigh more. Company-level distribution: II-2.

II-2. Distribution of R&D intensity

  1. The median company spends 9.4% of revenue on R&D.
  2. The median is highest in Biotech & drug discovery (46.4%) and lowest in Pharma & CDMO (5.8%).
  3. 42 companies exceed 50%, some spending more on R&D than they earn — development-stage companies with little revenue.
Figure II-2
Median company 9.4% — Biotech & drug discovery 46%, Healthcare infrastructure 1%
Median R&D-to-revenue ratio by sector (company level)
Biotech & drug discovery
46.4%n=68
Medical AI
19.4%n=12
Medical devices
9.9%n=67
Pharma & CDMO
5.8%n=98
Healthcare infrastructure
1.5%n=7
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
Sector (n)<5%5–10%10–20%20–50%50%+No revenueNot availableMedian
Pharma & CDMO41291925025.8%
Biotech & drug discovery95812292346.4%
Medical devices21132085009.9%
Medical AI113230219.4%
Healthcare infrastructure60010001.5%
All7848502542279.4%

"No revenue": zero half-year revenue. "Not available": no revenue line in the filed financials. From this edition ratios are recomputed on one definition rather than taken as self-reported (see method).

II-3. R&D at loss-making companies

  1. 114 of 244 companies reported an operating loss.
  2. They accounted for 32.5% of R&D spend.
  3. Among SMEs, 88 of 145 were loss-making.
Figure II-3a
114 loss-makers spend 32% of R&D
Share of companies with an operating loss, by sector
Biotech & drug discovery
74%n=65
Medical AI
60%n=10
Medical devices
39%n=66
Pharma & CDMO
33%n=96
Healthcare infrastructure
29%n=7
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
Figure II-3b
61% of SMEs are loss-making
Share loss-making, by company size
Large
27%n=11
Mid-sized
26%n=88
SME
61%n=145
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
SectorLoss-making (n)All (n)Share
Pharma & CDMO329633.3%
Biotech & drug discovery486573.8%
Medical devices266639.4%
Medical AI61060.0%
Healthcare infrastructure2728.6%
All11424446.7%
SizeLoss-making (n)All (n)Share
Large31127.3%
Mid-sized238826.1%
SME8814560.7%
All11424446.7%

II-4. Highest R&D intensity

Companies with at least KRW 5bn of half-year revenue, ranked by R&D intensity (small revenue makes ratios swing). LigaChem Biosciences Inc. is highest at 331.1%.

Figure II-4
LigaChem Biosciences Inc. spends 331% of revenue on R&D
Top ten by R&D intensity · half-year revenue at least KRW 5bn
LigaChem Biosciences Inc.
331.1%
SillaJen, Inc.
165.6%
ABL Bio Inc.
148.6%
MEDIPOSTCO.,LTD.
115.1%
Aimed Bio Inc.
84.1%
S.Biomedics Co., Ltd.
80.5%
TiumBio Co., Ltd.
73.8%
Cellid Co., Ltd.
69.7%
IMBiologics Corp.
50.8%
NEXTBIOMEDICAL Co., Ltd.
49.2%
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
RankCompanySectorRevenue (KRW bn)R&D (KRW bn)R&D / revenue
1LigaChem Biosciences Inc.Biotech & drug discovery41.4137.1331.1%
2SillaJen, Inc.Biotech & drug discovery5.18.4165.6%
3ABL Bio Inc.Biotech & drug discovery32.848.8148.6%
4MEDIPOSTCO.,LTD.Biotech & drug discovery38.244.0115.1%
5Aimed Bio Inc.Biotech & drug discovery28.724.184.1%
6S.Biomedics Co., Ltd.Pharma & CDMO9.27.480.5%
7TiumBio Co., Ltd.Biotech & drug discovery7.45.573.8%
8Cellid Co., Ltd.Biotech & drug discovery5.33.769.7%
9IMBiologics Corp.Biotech & drug discovery7.23.750.8%
10NEXTBIOMEDICAL Co., Ltd.Medical devices9.14.549.2%

II-5. Domestic and export sales

  1. Across the 137 companies whose sales table splits domestic and export sales, exports were 27.7% (the same definition as the Korea Biotechnology Industry Organization survey).
  2. Adding 35 companies whose split comes from the regional note (including overseas subsidiaries' local sales; Celltrion, Samsung Biologics) gives 38.5% for 172 companies — the figure and tables below use this combined base.
  3. On the combined base, Medical devices is highest by sector (59.2%) and large companies by size (73.8%).
Read with care — exports come from the sales table where available, otherwise from the regional note, whose overseas revenue includes overseas subsidiaries' local sales and is broader than exports. Celltrion and Samsung Biologics are on the note basis, which lifts the large-company figure.
Figure II-5
Medical devices earns 59% of sales from exports or overseas, the highest sector (combined base)
Domestic vs export, 172 companies (83% of revenue) · by sector and size
Pharma & CDMO
65%35%
Biotech & drug discovery
57%43%
Medical devices
41%59%
Medical AI
56%44%
Healthcare infrastructure
74%26%
Large
26%74%
Mid-sized
78%22%
SME
62%38%
DomesticExport & overseas (incl. note basis)
Includes 35 on note basis — see box · Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
SectorCompanies (n)Domestic (KRW bn)Export & overseas (KRW bn)Export & overseas shareFrom notes (n)
Pharma & CDMO7712,525.16,874.935.4%17
Biotech & drug discovery32590.5439.542.7%7
Medical devices491,179.51,710.859.2%9
Medical AI9151.8119.043.9%2
Healthcare infrastructure5329.6113.425.6%0
All17214,776.69,257.638.5%35
SizeCompanies (n)Domestic (KRW bn)Export & overseas (KRW bn)Export & overseas shareFrom notes (n)
Large81,789.85,044.273.8%4
Mid-sized7011,470.13,265.622.2%12
SME941,516.6947.838.5%19
All17214,776.69,257.638.5%35

The domestic/export split in the half-year sales table is used first (137 companies); where it is absent, the regional revenue note is used (35). The note's overseas revenue includes local sales of overseas subsidiaries and is broader than exports — Celltrion and Samsung Biologics are on the note basis.

II-6. Capital raising — equity and bonds

  1. From January 2024 to June 2026, 353 equity and bond issues worth KRW 8.95tn were decided.
  2. Working capital is the main stated use (66.6%); 86.0% of the amount was private or third-party placement.
  3. Counted at the decision; actual proceeds may be cancelled or reduced.
Figure II-6a
KRW 8.95tn over 2.5 years — KRW 3.60tn (2024), KRW 2.90tn (2025), KRW 2.44tn (H1 2026)
Issue decisions by period and type, KRW bn
2024
3,604.3
2025
2,898.5
H1 2026
2,444.9
Rights/placementConvertible bondsBonds with warrantsExchangeable bonds
Source: DART material-event reports (share and bond issuance decisions), Jan 2024–Jun 2026 · Analysis: MAA
Figure II-6b
67% of proceeds are earmarked for working capital
Stated use of proceeds
Working capital
66.6%
Equity stakes
10.9%
Capex
10.5%
Debt repayment
8.0%
Other
3.9%
Acquisitions
0.0%
Source: DART material-event reports (share and bond issuance decisions), Jan 2024–Jun 2026 · Analysis: MAA
SectorCompaniesRaisersRaised (KRW bn)2-yr raised / 2-yr R&D
Pharma & CDMO98452,303.325.8%
Biotech & drug discovery68455,007.8114.2%
Medical devices67311,129.771.6%
Medical AI127413.9193.5%
Healthcare infrastructure7492.987.6%
All2521328,947.759.4%

12 decisions without a stated amount are counted but not summed. "2-yr raised / 2-yr R&D" divides 2024–2025 decisions by the same companies' 2024–2025 R&D; it does not mean the money funded R&D.

II-7. How loss-makers keep funding research

  1. 76 of the 114 companies loss-making in H1 2026 (67%) decided an equity or bond issue in 2024–2025; 37 of 130 profitable companies did.
  2. Loss-makers' 2024–2025 issue decisions equal 142% of their R&D over the same years; for profitable companies, 19%.
  3. Medical AI is highest at 194% (sectors with 10+ companies).
Figure II-7a
Loss-makers decided to raise 1.4x their R&D
2024–2025 issue decisions ÷ same-period R&D, grouped by H1 2026 operating result
Loss-making
142%n=114
Profitable
19%n=130
Source: DART material-event reports (share and bond issuance decisions), Jan 2024–Jun 2026 · Analysis: MAA
Figure II-7b
LigaChem Biosciences Inc. decided the most, KRW 969.8bn
Top ten by issue decisions, KRW bn · Jan 2024–Jun 2026 · (loss) = loss-making in H1 2026
LigaChem Biosciences Inc. (loss)
969.8
Chabiotech Co.,Ltd. (loss)
486.4
HLB Co.,LTD. (loss)
367.8
Kolon TissueGene, Inc.
355.4
Aprogen Biologics Inc. (loss)
298.6
D&D Pharmatech Inc. (loss)
260.8
OliX Pharmaceuticals, Inc.
240.5
G2GBIO, Inc. (loss)
220.4
MEDIPOSTCO.,LTD. (loss)
205.0
PharmaResearch Co., Ltd.
200.0
Source: DART material-event reports (share and bond issuance decisions), Jan 2024–Jun 2026 · Analysis: MAA

Grouped by H1 2026 operating result (244 companies with revenue and operating profit, as in II-3), not by results at the time of issue. Counted at the decision; actual proceeds may differ.

III

III. People

Parent-company headcount, set against R&D. R&D headcount has no standard disclosure

88,589Employees+1.4%YoY
  • 88,589 staff at 242 companies, +1.4% year on year
  • Medical AI is lowest at -2.7% (sectors with 10+ companies)

III-1. Headcount and change

  1. The 242 companies with both years employed 88,589, +1.4% year on year.
  2. Medical devices grew most (+2.4%); Medical AI was lowest (-2.7%), among sectors with ten or more companies.
  3. R&D change (I-2) and headcount change cover different companies and perimeters (group vs parent), so their pace is not compared directly.
Figure III-1
Headcount +1.4% — only Medical AI fell
Parent-company headcount at period end, year-on-year change · companies with both years
By sector
Pharma & CDMO
+1.1%
Biotech & drug discovery
+1.5%
Medical devices
+2.4%
Medical AI
-2.7%
Healthcare infrastructure
+3.8%
By size
Large
+4.6%
Mid-sized
+0.8%
SME
+0.9%
Source: DART half-year filings and employee data · Analysis: MAA
SectorCompanies (n)H1 2025H1 2026Change
Pharma & CDMO9657,94358,609+1.1%
Biotech & drug discovery6611,21111,375+1.5%
Medical devices6214,62114,971+2.4%
Medical AI111,6481,604-2.7%
Healthcare infrastructure71,9552,030+3.8%
All24287,37888,589+1.4%
SizeCompanies (n)H1 2025H1 2026Change
Large1113,13113,733+4.6%
Mid-sized8655,14355,582+0.8%
SME14519,10419,274+0.9%
All24287,37888,589+1.4%

III-2. R&D per employee

  1. Among the 102 companies reporting R&D on a parent-only basis, H1 R&D per employee was KRW 23m on totals; the company median was KRW 16m.
  2. Because headcount is parent-only, companies reporting consolidated R&D are excluded — dividing group R&D by parent staff would overstate it.
Figure III-2
Biotech & drug discovery spends the most per head, KRW 45m
H1 R&D per employee, KRW m · 102 companies reporting parent-only R&D
Biotech & drug discovery
45n=34
Medical AI
19n=4
Pharma & CDMO
18n=42
Medical devices
15n=21
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
SectorCompanies (n)Per head (KRW m)Median (KRW m)
Pharma & CDMO421810
Biotech & drug discovery344543
Medical devices211514
Medical AI41917
Healthcare infrastructure———
All1022316
SizeCompanies (n)Per head (KRW m)Median (KRW m)
Large33711
Mid-sized331913
SME663121
All1022316
IV

IV. Investment and output

Two years of R&D spend (2024–2025) joined, company by company, to the approvals, trials, publications and patents disclosed over the same period — what R&D-only tallies cannot show.

KRW 11.14tnTwo-year R&D1,874Approvals1,081Papers
  • The top 10% (26) hold 61% of R&D and 65% of global trials
  • Per KRW 10bn, approvals peak in Medical devices, papers in Medical AI
  • 34 companies in phase 3 · 25 out-licensing deals
  • 7 companies disclosed no output at all

IV-1. Two years of spend and disclosed output, by sector

Pharma & CDMO (97 companies) accounts for 56.8% of 2024–2025 R&D. Per KRW 10bn, the leading sector is Medical devices for approvals, Pharma & CDMO for Korean trials, Medical AI for global trials, Medical AI for publications and Medical AI for patents.

Figure IV-1
Same money, different output — approvals in Medical devices, papers and patents in Medical AI
Disclosed output per KRW 10bn by sector · 2024–2025 (patents 2023–2024) · sectors with 10+ companies
Approvals (n)
Pharma & CDMO
1.72
Biotech & drug discovery
0.34
Medical devices
4.64
Medical AI
2.80
Papers (n)
Pharma & CDMO
0.60
Biotech & drug discovery
0.97
Medical devices
1.58
Medical AI
9.28
Patents (n)
Pharma & CDMO
1.91
Biotech & drug discovery
3.31
Medical devices
10.66
Medical AI
15.99
Source: DART, MFDS, US FDA, ClinicalTrials.gov, PubMed, KIPRIS, 2024–2025 · Analysis: MAA
SectorCompanies (n)R&D (KRW bn)approvals (n)Korean trials (n)global trials (n)publications (n)patents (n)
Pharma & CDMO976,332.21,0912312013781,116
Biotech & drug discovery753,296.11124645320961
Medical devices691,279.85944142021,241
Medical AI12182.15106169235
Healthcare infrastructure750.226311283
Sector · per KRW 10bnapprovals (n)Korean trials (n)global trials (n)publications (n)patents (n)
Pharma & CDMO1.720.360.320.601.91
Biotech & drug discovery0.340.140.140.973.31
Medical devices4.640.030.111.5810.66
Medical AI2.800.000.339.2815.99
Healthcare infrastructure5.180.600.202.3915.11
All1.680.250.240.973.60

Sector leaders are chosen among sectors with at least 10 companies — small denominators swing. Patents are published 18 months after filing, so 2023–2024 filings are divided by 2023–2024 R&D.

IV-2. Concentration

The top 10% of spenders (26 companies) account for 61.1% of two-year R&D. They also hold 64.8% of global trial starts and 51.1% of Korean trial authorisations — the costlier the stage, the more concentrated. Approvals (23.2%) and patents (23.8%) are broadly spread.

Figure IV-2
Top 10% hold 61% of R&D; global trials 65% even more; approvals 23%, patents 24% broadly spread
Share held by the top 10% of spenders (26 companies) · 2024–2025
R&D
61.1%
Approvals
23.2%
Korean trials
51.1%
Global trials
64.8%
Papers
32.6%
Patents
23.8%
Source: DART, MFDS, US FDA, ClinicalTrials.gov, PubMed, KIPRIS, 2024–2025 · Analysis: MAA

IV-3. Approvals and trials per KRW 10bn

Companies with at least KRW 5bn of two-year R&D, ranked by approvals (top) and Korean trial authorisations (bottom) per KRW 10bn. This is not an efficiency measure — a generic and a new drug, or a Class 2 certification and a Class 4 approval, each count as one. It shows what form of public record the spend took.

Figure IV-3
SINSIN PHARMACEUTICAL Co., LTD. leads with 44.9 approvals per KRW 10bn
Approvals per KRW 10bn, companies with at least KRW 5bn of two-year R&D — not an efficiency measure
SINSIN PHARMACEUTICAL Co., LTD.
44.9
DongBang Medical Co., Ltd.
40.8
Precision Biosensor Inc.
32.4
KOREA ARLICO PHARM CO.,LTD.
29.8
CMG Pharmaceutical Co., Ltd.
29.6
Coreline Soft Co., Ltd
26.4
SHINIL PHARMACEUTICAL CO., LTD.
23.2
DIO Corporation
19.3
Yuyu Pharma, Inc.
18.3
DONGSUNG PHARMACEUTICAL CO.,LTD
16.8
Source: DART, MFDS, US FDA, ClinicalTrials.gov, PubMed, KIPRIS, 2024–2025 · Analysis: MAA
RankCompanyTwo-year R&D (KRW bn)approvals (n)Per KRW 10bn (n)
1SINSIN PHARMACEUTICAL Co., LTD.5.32444.9
2DongBang Medical Co., Ltd.5.92440.8
3Precision Biosensor Inc.6.22032.4
4KOREA ARLICO PHARM CO.,LTD.10.13029.8
5CMG Pharmaceutical Co., Ltd.17.65229.6
6Coreline Soft Co., Ltd6.11626.4
7SHINIL PHARMACEUTICAL CO., LTD.8.62023.2
8DIO Corporation9.31819.3
9Yuyu Pharma, Inc.8.21518.3
10DONGSUNG PHARMACEUTICAL CO.,LTD8.31416.8
RankCompanyTwo-year R&D (KRW bn)Korean trials (n)Per KRW 10bn (n)
1SINSIN PHARMACEUTICAL Co., LTD.5.323.7
2C&R Research Inc.6.323.2
3KOREA ARLICO PHARM CO.,LTD.10.133.0
4REYON PHARMACEUTICAL CO., LTD7.722.6
5Aprogen Biologics Inc.23.752.1
6SEOUL PHARMA CO.,LTD5.411.9
7Daehan Nupharm Co.,Ltd.16.831.8
8DAEWON PHARMACEUTICAL CO.,LTD101.1181.8
9Boryung Corporation124.7221.8
10Hana Pharm. Co., Ltd.29.351.7

IV-4. Publications per KRW 10bn

On the same basis, PubMed-indexed publications per KRW 10bn. Medical AI companies feature prominently.

Figure IV-4
3billion Inc. leads with 83.5 papers per KRW 10bn
Papers per KRW 10bn, companies with at least KRW 5bn of two-year R&D — not an efficiency measure
3billion Inc.
83.5
Optipharm.CO.,LTD
30.2
Future Medicine Co., Ltd.
28.5
Coreline Soft Co., Ltd
26.4
NEUROPHET Inc.
23.6
VUNO, Inc.
19.7
HEM Pharma Inc.
14.2
Oncocross Co.,Ltd.
12.8
ORGANOIDSCIENCES LTD.
11.9
DEEPNOID Inc.
11.4
Source: DART, MFDS, US FDA, ClinicalTrials.gov, PubMed, KIPRIS, 2024–2025 · Analysis: MAA
RankCompanyTwo-year R&D (KRW bn)publications (n)Per KRW 10bn (n)
13billion Inc.7.76483.5
2Optipharm.CO.,LTD8.92730.2
3Future Medicine Co., Ltd.6.71928.5
4Coreline Soft Co., Ltd6.11626.4
5NEUROPHET Inc.12.73023.6
6VUNO, Inc.11.22219.7
7HEM Pharma Inc.7.11014.2
8Oncocross Co.,Ltd.6.3812.8
9ORGANOIDSCIENCES LTD.11.01311.9
10DEEPNOID Inc.12.31411.4

IV-5. Companies with no disclosed output

7 companies with KRW 26.4bn of two-year R&D had no approval, trial, publication or patent disclosed over the same period (Pharma & CDMO 3 · Medical AI 1 · Healthcare infrastructure 1 · Biotech & drug discovery 1 · Medical devices 1). Many are early-stage or file through overseas partners, so they are not named.

IV-6. Pipeline by phase

  1. 2024–2025 Korean authorisations (excluding bioequivalence): phase 1 208, phase 2 32, phase 3 43; global starts: phase 1 140, phase 2 29, phase 3 52.
  2. 224 bioequivalence studies (for generics) are counted separately.
  3. 34 companies have a phase 3 trial; 53 global phase 3 trials are ongoing.
Figure IV-6a
Mostly phase 1 — 95 phase 3 trials, Korea and global combined
Korean authorisations + global starts, 2024–2025, by phase and sector (excl. bioequivalence)
Pharma & CDMO
406
Biotech & drug discovery
86
Medical devices
8
Healthcare infrastructure
4
Phase 1Phase 2Phase 3
Source: MFDS trial authorisations · ClinicalTrials.gov, 2024–2025 · Analysis: MAA
Figure IV-6b
Phase 3 is concentrated — Celltrion, Inc. leads with 13
Top companies by phase 3 trials, 2024–2025
Celltrion, Inc.
13
YUHAN CORPORATION
11
DAEWOONG PHARMA
10
DAEWON PHARMACEUTICAL CO.,LTD
7
Hanmi Pharm. Co., Ltd.
6
JW PHARMACEUTICAL
5
AHN-GOOK PHARMACEUTICAL Co., Ltd.
4
Chong Kun Dang Pharmaceutical Corp.
4
HK inno.N Corporation
4
ILYANG PHARMACEUTICAL CO.,LTD
3
Source: MFDS trial authorisations · ClinicalTrials.gov, 2024–2025 · Analysis: MAA
SectorKR P1KR P2KR P3KR otherGl P1Gl P2Gl P3Gl otherBE
Pharma & CDMO17716380115134726201
Biotech & drug discovery27135124134413
Medical devices31001211010
Medical AI000000060
Healthcare infrastructure120001000
All20832431140295246224

Combined phases count at the higher phase. "Other" covers phase 4 and studies without a phase (e.g. device trials); IV-1 totals equal the sum including "other". Global trials only where the company or a confirmed subsidiary is the lead sponsor. Ongoing counts are as of the computation date.

IV-7. Licensing — when research earns money

  1. From January 2024 to June 2026, 17 companies disclosed 25 out-licensing deals; 23 in-licensing deals and 13 terminations.
  2. The 15 deals with a disclosed KRW value total KRW 15.26tn; the 17 with a disclosed upfront total KRW 522.9bn. The 3 deals stated only in foreign currency are not summed, and 6 deals kept amounts confidential.
  3. Headline deal values are mostly contingent milestones; only upfronts and milestones achieved are received.
Figure IV-7
ABL Bio Inc. signed the largest, KRW 4.11tn
Largest out-licensing deals with a disclosed KRW value, KRW bn
ABL Bio Inc. → GSK (GlaxoSmithKline)
4,110.4
ABL Bio Inc. → Eli Lilly and Company
3,807.2
Hanmi Pharm. Co., Ltd. → Eli Lilly and Company
1,897.3
LigaChem Biosciences Inc. → ONO PHARMACEUTICAL CO.
943.5
OliX Pharmaceuticals, Inc. → Eli lilly and company
911.7
Alteogen Inc. → Biogen International G
867.5
curacle co., ltd. → Memento Medicines
781.8
NIBEC CO., LTD. → A US biopharma company
595.3
Genome&Company → Debiopharm
586.4
Alteogen Inc. → Tesaro, Inc.
420.0
Source: KRX disclosures (material management matters), Jan 2024–Jun 2026 · Analysis: MAA
DateCompanyCounterpartyTotal (KRW bn)Upfront (KRW bn)
2025-04-07ABL Bio Inc.GSK (GlaxoSmithKline)4,110.473.9
2025-11-12ABL Bio Inc.Eli Lilly and Company3,807.258.5
2026-06-01Hanmi Pharm. Co., Ltd.Eli Lilly and Company1,897.3112.9
2024-10-10LigaChem Biosciences Inc.ONO PHARMACEUTICAL CO., LTD.943.5—
2025-02-07OliX Pharmaceuticals, Inc.Eli lilly and company911.7—
2026-03-25Alteogen Inc.Biogen International GMBH867.530.0
2026-05-11curacle co., ltd.Memento Medicines781.85.8
2025-05-28NIBEC CO., LTD.A US biopharma company (undisc595.310.9
2024-06-03Genome&CompanyDebiopharm586.46.9
2026-01-20Alteogen Inc.Tesaro, Inc.420.029.5
2024-05-02MOA Life Plus Co. Ltd.Elevai Labs, Inc.180.71.5
2024-06-26ISU Abxis Co., Ltd.A US oncology developer (undis118.54.2
2024-09-09ENCell Co., Ltd.Lucy Biotech25.92.0
2024-11-07KANGSTEM BIOTECH CO., LTD.Yuyoung Pharm14.0—
2025-12-16SyntekaBio,Inc.Panoros Bioscience2.50.5
2025-03-04AbClon Inc.TCT Health Technologyn/d—
2024-07-30Alteogen Inc.Sandoz AGn/d—
2024-11-08Alteogen Inc.Daiichi Sankyon/d28.0
2025-03-17Alteogen Inc.MedImmune, LLCn/d29.1
2025-03-17Alteogen Inc.MedImmune Limitedn/d36.4
2026-03-16G2GBIO, Inc.Samsung Bioepis · Epis NexLabn/d—
2024-10-10LigaChem Biosciences Inc.ONO PHARMACEUTICAL CO., LTD.n/d—
2025-12-16OSCOTECInc.ADEL and Sanofin/d55.3
2026-06-01OSCOTECInc.Agios Pharmaceuticals, Inc.n/d37.5
2025-05-13Y-Biologics, IncLigaChem Biosciencesn/d—

Only KRW amounts stated in the filing are used (no exchange rate applied by us). Amendments, assignments and duplicate filings are excluded. Two deals with the same partner on the same day count separately (LigaChem–ONO: the LCB97 asset deal and the multi-target ADC research deal). Each filing was read and every figure checked against a verbatim quote of the source.

V

V. The largest spenders up close

The ten largest two-year spenders — trend, financial context and disclosed output

KRW 4.39tnTwo-year R&D, top ten39.4%Share of all
  • Celltrion, Inc. leads with KRW 902.4bn over two years

V-1. Celltrion, Inc.

Celltrion, Inc. spent KRW 284.3bn on R&D in H1 2026 (+23.8% YoY), 11.2% of revenue. Over two years it spent KRW 902.4bn; disclosed output over the same period: Approvals 20 · Korean trials 18 · Global trials 13 · Papers 36 · Patents 46.

Figure V-1
R&D trend — H1 2026 +23.8%
Annual and half-year R&D, KRW bn
Annual
2023
342.7
2024
420.0
2025
482.4
First half
H1 2025
229.7
H1 2026
284.3
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisPharma & CDMO · Large · consolidated
H1 revenue (KRW bn)2,538.7
H1 operating profit (KRW bn)773.7
Capitalised share of R&D55.7%
Employees (period end)3,172
Export share72.6% (note basis)

V-2. YUHAN CORPORATION

YUHAN CORPORATION spent KRW 122.2bn on R&D in H1 2026 (+13.8% YoY), 10.5% of revenue. Over two years it spent KRW 511.2bn; disclosed output over the same period: Approvals 31 · Korean trials 9 · Global trials 26 · Papers 27 · Patents 55.

Figure V-2
R&D trend — H1 2026 +13.8%
Annual and half-year R&D, KRW bn
Annual
2023
194.5
2024
268.8
2025
242.4
First half
H1 2025
107.3
H1 2026
122.2
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisPharma & CDMO · Mid-sized · consolidated
H1 revenue (KRW bn)1,166.2
H1 operating profit (KRW bn)75.7
Capitalised share of R&D0.8%
Employees (period end)2,145
Export share19.5%

V-3. DAEWOONG PHARMA

DAEWOONG PHARMA spent KRW 115.7bn on R&D in H1 2026 (+8.5% YoY), 15.7% of revenue. Over two years it spent KRW 454.5bn; disclosed output over the same period: Approvals 50 · Korean trials 17 · Global trials 21 · Papers 27 · Patents 87.

Figure V-3
R&D trend — H1 2026 +8.5%
Annual and half-year R&D, KRW bn
Annual
2023
206.6
2024
234.6
2025
219.9
First half
H1 2025
106.6
H1 2026
115.7
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisPharma & CDMO · Mid-sized · separate
H1 revenue (KRW bn)735.9
H1 operating profit (KRW bn)104.6
Capitalised share of R&D10.9%
Employees (period end)1,972
Export share20.6%

V-4. Hanmi Pharm. Co., Ltd.

Hanmi Pharm. Co., Ltd. spent KRW 125.5bn on R&D in H1 2026 (+18.2% YoY), 14.6% of revenue. Over two years it spent KRW 438.8bn; disclosed output over the same period: Approvals 23 · Korean trials 9 · Global trials 12 · Papers 72 · Patents 114.

Figure V-4
R&D trend — H1 2026 +18.2%
Annual and half-year R&D, KRW bn
Annual
2023
205.0
2024
209.8
2025
229.0
First half
H1 2025
106.2
H1 2026
125.5
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisPharma & CDMO · Mid-sized · consolidated
H1 revenue (KRW bn)860.2
H1 operating profit (KRW bn)184.7
Capitalised share of R&D7.3%
Employees (period end)2,424
Export share21.4%

V-5. SAMSUNG EPIS HOLDINGS Co., Ltd.

SAMSUNG EPIS HOLDINGS Co., Ltd. spent KRW 106.0bn on R&D in H1 2026, 12.5% of revenue. Over two years it spent KRW 419.2bn; disclosed output over the same period: Approvals 13 · Korean trials 0 · Global trials 2 · Papers 22 · Patents 10. Its consolidation scope changed (e.g. a demerger), so period values cover different perimeters.

Figure V-5
R&D trend — periods cover different perimeters
Annual and half-year R&D, KRW bn
Annual
2023
—
2024
171.8
2025
247.4
First half
H1 2025
—
H1 2026
106.0
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisPharma & CDMO · Large · consolidated
H1 revenue (KRW bn)845.8
H1 operating profit (KRW bn)149.3
Capitalised share of R&D34.2%
Employees (period end)10
Export share94.0%

V-6. GC Biopharma Corp.

GC Biopharma Corp. spent KRW 85.9bn on R&D in H1 2026 (+3.8% YoY), 10.0% of revenue. Over two years it spent KRW 346.6bn; disclosed output over the same period: Approvals 36 · Korean trials 5 · Global trials 3 · Papers 14 · Patents 27.

Figure V-6
R&D trend — H1 2026 +3.8%
Annual and half-year R&D, KRW bn
Annual
2023
195.4
2024
174.7
2025
171.9
First half
H1 2025
82.7
H1 2026
85.9
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisPharma & CDMO · Mid-sized · consolidated
H1 revenue (KRW bn)856.7
H1 operating profit (KRW bn)13.5
Capitalised share of R&D7.6%
Employees (period end)2,422
Export share32.6%

V-7. Chong Kun Dang Pharmaceutical Corp.

Chong Kun Dang Pharmaceutical Corp. spent KRW 113.5bn on R&D in H1 2026 (+36.6% YoY), 12.3% of revenue. Over two years it spent KRW 343.2bn; disclosed output over the same period: Approvals 55 · Korean trials 16 · Global trials 22 · Papers 7 · Patents 75.

Figure V-7
R&D trend — H1 2026 +36.6%
Annual and half-year R&D, KRW bn
Annual
2023
151.3
2024
157.4
2025
185.8
First half
H1 2025
83.1
H1 2026
113.5
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisPharma & CDMO · Mid-sized · consolidated
H1 revenue (KRW bn)926.2
H1 operating profit (KRW bn)32.7
Capitalised share of R&D28.1%
Employees (period end)2,285
Export share4.0%

V-8. SK biopharmaceuticals Co., Ltd.

SK biopharmaceuticals Co., Ltd. spent KRW 97.3bn on R&D in H1 2026 (+19.2% YoY), 20.5% of revenue. Over two years it spent KRW 335.6bn; disclosed output over the same period: Approvals 0 · Korean trials 0 · Global trials 1 · Papers 3 · Patents 29.

Figure V-8
R&D trend — H1 2026 +19.2%
Annual and half-year R&D, KRW bn
Annual
2023
137.1
2024
161.3
2025
174.3
First half
H1 2025
81.6
H1 2026
97.3
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisBiotech & drug discovery · Large · consolidated
H1 revenue (KRW bn)475.3
H1 operating profit (KRW bn)186.8
Capitalised share of R&D—
Employees (period end)278
Export share—

V-9. LigaChem Biosciences Inc.

LigaChem Biosciences Inc. spent KRW 137.1bn on R&D in H1 2026 (+77.4% YoY), 331.1% of revenue. Over two years it spent KRW 330.4bn; disclosed output over the same period: Approvals 0 · Korean trials 0 · Global trials 1 · Papers 3 · Patents 33.

Figure V-9
R&D trend — H1 2026 +77.4%
Annual and half-year R&D, KRW bn
Annual
2023
81.0
2024
113.3
2025
217.1
First half
H1 2025
77.3
H1 2026
137.1
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisBiotech & drug discovery · Mid-sized · consolidated
H1 revenue (KRW bn)41.4
H1 operating profit (KRW bn)-109.4
Capitalised share of R&D0.0%
Employees (period end)190
Export share—

V-10. SAMSUNG BIOLOGICS CO.,LTD.

SAMSUNG BIOLOGICS CO.,LTD. spent KRW 81.9bn on R&D in H1 2026, 3.2% of revenue. Over two years it spent KRW 309.0bn; disclosed output over the same period: Approvals 0 · Korean trials 0 · Global trials 0 · Papers 3 · Patents 21. Its consolidation scope changed (e.g. a demerger), so period values cover different perimeters.

Figure V-10
R&D trend — periods cover different perimeters
Annual and half-year R&D, KRW bn
Annual
2023
325.3
2024
141.6
2025
167.4
First half
H1 2025
228.6
H1 2026
81.9
Source: DART half-year filings (August 2026) and financial API · Analysis: MAA
ItemValue
Sector · size · basisPharma & CDMO · Large · consolidated
H1 revenue (KRW bn)2,578.0
H1 operating profit (KRW bn)1,167.2
Capitalised share of R&D0.0%
Employees (period end)5,573
Export share83.3% (note basis)

What the numbers say

  1. R&D is concentrated. The top twenty account for 58.2% of H1 spend; on a two-year basis the top 10% (26 companies) account for 61.1%. Sector totals move with these companies.
  2. 32.5% of R&D comes from loss-making companies — spending not covered by that period's operating profit.
  3. The same spend is accounted for differently. 15.8% was capitalised overall, with wide differences by sector and company — relevant when comparing profits.
  4. Self-reported ratios are not always comparable. For 11 companies the disclosed R&D ratio departs from the filing form's own formula (pre-grant R&D ÷ revenue). This report recomputes all ratios on one definition.

Method and limits

R&D spend — the "total R&D expense" line of half-year and annual filings, before government grants, consolidated where available. Only values that pass a cross-check (e.g. against the disclosed ratio) are used: a verified census, not a sample.

Non-healthcare companies excluded — 19 companies whose company-wide R&D is mostly unrelated to healthcare: AHNLAB,INC. (security software) · Chunbo Co., Ltd. (battery & display materials) · CJ CHEILJEDANG CORP. (food) · COSMAX BTI, INC. (cosmetics holding company) · COSMAX NBT, INC. (dietary supplements) · HLSCIENCE Co., LTD (dietary supplements) · HYUNDAI ELEVATOR CO.,LTD (elevators) · INTOPS CO., LTD. (handset & appliance parts) · KOLMAR KOREA CO.,LTD (cosmetics contract manufacturing) · Kwangdong Healthbio Co., Ltd. (dietary supplements) · NOVAREX Co., Ltd. (dietary supplements) · NUON CO., LTD. (dietary supplements) · PAKERS CO., Ltd. (printer parts & lighting) · RN2 Technologies Co., Ltd. (telecom components) · S&D Co., Ltd (supplement ingredients) · SBSUNGBO Co., Ltd. (agrochemicals) · SK Innovation Co., Ltd. (refining & batteries) · WonIk Co.,LTD (quartz & semiconductor parts) · WOOREE BIO CO., LTD (dietary supplements).

Holding companies and parents — 10 companies that consolidate listed subsidiaries (nine holding companies and SK Chemicals, parent of SK bioscience) are excluded to avoid double counting: DAEWOONG CO.,LTD · CHONGKUNDANG HOLDINGS CORP. · GC Corp. · JW HOLDINGS CORPORATION · JEIL PHARMA HOLDINGS INC. · ILDONG HOLDINGS CO.,LTD · Huons Global Co., Ltd. · Dong-A Socio Holdings Co.,Ltd · Hanmi Science Co.,Ltd · SK Chemicals Co., Ltd.. Samsung Epis Holdings, whose subsidiary is unlisted, is included.

Year-on-year comparison — only companies with both half-year values on the same consolidation basis. Samsung Biologics (scope changed by the November 2025 demerger) and Samsung Epis Holdings (no prior-year value) are excluded from the comparison.

Output — approvals: MFDS Class 2 device certifications, Class 3–4 device approvals and drug approvals, plus US FDA 510(k) and drug approvals. Class 1 devices, which are only notified without review (242 in the period), are not counted as approvals. Korean trials: MFDS trial authorisations. Global trials: ClinicalTrials.gov start dates. Publications: PubMed author affiliation. Patents: KIPRIS filings, domestic and foreign. Window 2024–2025; patents 2023–2024.

Matching and subsidiaries — records are matched by business registration number or exact corporate name; similarity matching is never used. Approvals, trials and patents filed by subsidiaries whose control is confirmed in filings are counted under the listed parent. Publications are counted by the listed company's own author affiliation only and exclude subsidiary-affiliated papers — except Samsung Epis Holdings, a holding company whose research is carried out entirely by its wholly owned subsidiary Samsung Bioepis, which is counted by that affiliation.

Direction of error — approvals filed by overseas affiliates or partners, CRO-sponsored trials, records of unconfirmed subsidiaries, papers published under a subsidiary's affiliation and global trials whose sponsor name differs sharply from the company name can be missed (undercount). Conversely, patents are counted per filing, so one invention filed in several countries counts several times (overcount), and exact-name matching can rarely attach the wrong company. In this edition 465 global trials at 12 companies, previously missed through name variants, were linked after source checks.

Company size — as each company declares it in its periodic filing (SME / mid-sized status). SMEs meet the Framework Act on SMEs criteria (sector revenue thresholds — KRW 80bn for drug and device manufacturing — total assets under KRW 500bn, independence); mid-sized companies meet the Mid-sized Enterprises Act criteria; large companies are neither. A statutory three-year grace period means some SMEs have large revenue.

Financials — half-year revenue and operating profit from the DART financial API, on the same consolidated or separate basis as each company's R&D. 1,016 values match the XBRL in the filings, a consistency check within one source that cannot catch currency or unit errors — non-KRW filers are screened out separately.

R&D intensity — total R&D expense before grants ÷ revenue × 100, the formula set by the filing form. For 11 companies the self-reported ratio departs from it (usually computed after grants), so the recomputed value is used. The first edition (September 2026) used self-reported ratios for sector medians; from this edition all ratios are recomputed.

Accounting and nature — from the same table as the R&D total, only where lines sum to the total (±1%). Grants are not re-allocated across lines.

Domestic vs export — the sales table's split (domestic + export = total = reported revenue, ±3%) first; otherwise the regional revenue note (domestic / overseas), which includes overseas subsidiaries' local sales. The CSV states which source each company uses.

Headcount — parent-company staff at period end, including fixed-term. Subtotal rows are removed by structure (a row equal to the sum of the others), not by label, to avoid double counting. R&D headcount has no standardised disclosure and is not reported.

Pipeline — Korean MFDS trial authorisations (2024–2025) and ClinicalTrials.gov studies with the company as lead sponsor, by start date (2024–2025). Bioequivalence studies, run to launch generics, are counted separately from Korean trials (the first edition mixed them). Combined phases count at the higher one.

Capital raising — rights issues, placements, convertible bonds, bonds with warrants and exchangeable bonds decided in material-event reports (Jan 2024–Jun 2026, board resolution date). Amounts sum the stated uses of proceeds and count at the decision; actual proceeds may differ. Bonus issues are excluded. "Raised / R&D" does not imply the money funded R&D.

Licensing — each KRX disclosure of material management matters was read; only new deals are counted (amendments, assignments and duplicates excluded). Only KRW amounts stated in the filing are used; foreign-currency-only amounts are left blank. Headline values are mostly contingent milestones.

Population — of the 422 index companies, 281 have an R&D table that passed our cross-check, 65 did not pass, 60 have no R&D disclosure or DART code, and 16 were excluded (non-December year-end or holding company). Of the 270 with a verified H1 2026 value, 18 non-healthcare companies are removed, leaving 252. Companies verified but without an H1 value (e.g. those filing an annual report instead) appear only in the two-year metrics (IV). Financials are used only when filed in KRW (Kolon TissueGene reports in US dollars and is left out of financial tables).

Korean reports compared — "the Korean reports we reviewed" are the Korea Biotechnology Industry Organization's listed-company survey, KBIOIS in-depth analyses and briefs, and press tallies of half-year R&D (e.g. Medipana). Where a consolidated subsidiary is separately listed (e.g. Celltrion and Celltrion Pharm), both are counted unless the parent is a holding company, so totals may overlap slightly.

Table cells — cells with fewer than three companies are shown as "—": they would reveal a single company and are not representative. Ratios on totals weigh large companies more.

Edition history — first edition 2026-09-24 (R&D and disclosed output) → full edition 2026-10-07 (this one). Added: financials, people, export sales, capital raising, pipeline and licensing; R&D intensity recomputed with the filing-form formula; bioequivalence removed from Korean trials; 465 global trials at 12 companies and three sector classifications corrected. Corrections are logged.

Verification — ranked figures were recounted from the raw collection files. R&D was checked against the ratio companies state in the same table; capital raising against the count of decision filings in the disclosure index; licensing amounts against verbatim quotes of the filing (independent paths). Financial API values were also matched to the filings' XBRL, which confirms consistency within one source. Reported errors are recomputed and corrected with a visible history.

Appendix. Company table

All 252 companies, ordered by H1 2026 R&D spend: investment and financials above, two-year output below (same ranking). Company data with more columns (revenue, operating profit, headcount, export share) can be downloaded as CSV from "Download company data" at the top of the report or at medicalaialliance.org/reports/rnd-invest-2026h1.csv.

RankCompanySectorSizeH1 2026 (KRW bn)YoYR&D / revenue
1Celltrion, Inc.Pharma & CDMOLarge284.3+23.8%11.2%
2LigaChem Biosciences Inc.Biotech & drug discoveryMid-sized137.1+77.4%331.1%
3Hanmi Pharm. Co., Ltd.Pharma & CDMOMid-sized125.5+18.2%14.6%
4SK Bioscience Co.,LtdBiotech & drug discoveryLarge122.4+80.0%37.7%
5YUHAN CORPORATIONPharma & CDMOMid-sized122.2+13.8%10.5%
6DAEWOONG PHARMAPharma & CDMOMid-sized115.7+8.5%15.7%
7Chong Kun Dang Pharmaceutical Corp.Pharma & CDMOMid-sized113.5+36.6%12.3%
8SAMSUNG EPIS HOLDINGS Co., Ltd.Pharma & CDMOLarge106.0—12.5%
9SK biopharmaceuticals Co., Ltd.Biotech & drug discoveryLarge97.3+19.2%20.5%
10GC Biopharma Corp.Pharma & CDMOMid-sized85.9+3.8%10.0%
11SAMSUNG BIOLOGICS CO.,LTD.Pharma & CDMOLarge81.9—3.2%
12DONG-A ST CO.,LTDPharma & CDMOMid-sized55.2-8.5%12.9%
13ABL Bio Inc.Biotech & drug discoverySME48.8-8.9%148.6%
14Kolon TissueGene, Inc.Biotech & drug discoveryLarge48.0-11.4%—
15MEDIPOSTCO.,LTD.Biotech & drug discoverySME44.0+28.3%115.1%
16JW PHARMACEUTICALPharma & CDMOMid-sized43.1-11.5%10.2%
17SD BIOSENSOR INC.Medical devicesMid-sized42.9+18.8%11.3%
18HK inno.N CorporationPharma & CDMOMid-sized42.6+12.8%8.1%
19Voronoi, Inc.Biotech & drug discoverySME41.7+95.4%—
20JEIL PHARMACEUTICAL CO.,LTDPharma & CDMOMid-sized35.9+68.4%13.0%
21Orum Therapeutics, Inc.Biotech & drug discoverySME35.2+62.5%1,000%+
22Boryung CorporationPharma & CDMOMid-sized28.6-10.4%5.4%
23SEEGENE, INC.Medical devicesMid-sized26.1-22.2%9.9%
24Aimed Bio Inc.Biotech & drug discoverySME24.1—84.1%
25IL DONG PHARMACEUTICAL CO., LTD.Pharma & CDMOMid-sized23.9+38.6%8.3%
26PharmaResearch Co., Ltd.Medical devicesMid-sized23.8+48.8%7.3%
27DAEWON PHARMACEUTICAL CO.,LTDPharma & CDMOMid-sized23.6-4.5%7.6%
28Medy-Tox Inc.Pharma & CDMOMid-sized22.3+1.1%17.3%
29SAM CHUN DANG PHARM CO. LTDPharma & CDMOMid-sized21.7+390.3%16.0%
30HLB Co.,LTD.Biotech & drug discoveryMid-sized21.7-15.8%46.5%
31HUONS CO., LTD.Pharma & CDMOMid-sized21.5+9.1%7.4%
32GI Innovation Inc.Biotech & drug discoverySME21.2+26.8%—
33i-SENS, Inc.Medical devicesMid-sized20.7+39.4%12.6%
34OliX Pharmaceuticals, Inc.Biotech & drug discoverySME18.5+40.7%—
35KOREA UNITED PHARM INCBiotech & drug discoveryMid-sized17.6+3.6%11.6%
36ILYANG PHARMACEUTICAL CO.,LTDBiotech & drug discoveryMid-sized17.4+21.5%13.3%
37DongKookPharmaceuticalCo.,Ltd.Pharma & CDMOMid-sized17.3+15.7%4.0%
38Qurient Co., Ltd.Biotech & drug discoverySME16.5+64.7%429.3%
39SAMJIN PHARMACEUTICAL CO.,LTDPharma & CDMOMid-sized16.3-3.1%11.1%
40Mezzion Pharma Co., Ltd.Biotech & drug discoverySME15.8+128.6%375.2%
41KYONGBO PHARMACEUTICAL CO., LTD.Pharma & CDMOMid-sized15.2+42.8%10.8%
42OSCOTECInc.Biotech & drug discoverySME15.0+20.6%26.7%
43BUKWANG PHARMACEUTICAL IND CO.,LTDPharma & CDMOLarge14.9+27.9%14.3%
44CLASSYS Inc.Medical devicesMid-sized14.6+37.3%7.6%
45Lunit Inc.Medical AISME14.4-24.3%31.5%
46HANALL BIOPHARMA CO.,LTDPharma & CDMOMid-sized14.3-22.4%16.9%
47ST PHARM CO., LTD.Pharma & CDMOMid-sized13.8+18.8%7.9%
48Rznomics Inc.Biotech & drug discoverySME13.5—1,000%+
49GC CELL CORPORATIONBiotech & drug discoveryMid-sized13.4-2.4%16.9%
50D&D Pharmatech Inc.Biotech & drug discoverySME13.1+0.9%1,000%+
51Genexine, Inc.Biotech & drug discoverySME12.8+19.9%920.1%
52Inventage Lab Inc.Biotech & drug discoverySME12.7+30.6%1,000%+
53Vieworks Co., Ltd.Medical devicesMid-sized12.5-3.9%10.3%
54Curocell Inc.Biotech & drug discoverySME12.2-24.2%—
55DONGWHA PHARM.CO.,LTDPharma & CDMOMid-sized12.0-3.5%4.5%
56Boditech Med Inc.Medical devicesMid-sized11.8+24.8%12.6%
57BIONEERCORPORATIONMedical devicesMid-sized11.3+54.9%6.3%
58HANDOK Inc.Pharma & CDMOMid-sized11.2-1.7%4.1%
59SHINPOONG PHARMACEUTICAL CO.,LTDPharma & CDMOMid-sized10.9—9.2%
60Chabiotech Co.,Ltd.Biotech & drug discoveryMid-sized10.8-11.0%1.7%
61Samyang Biopharm CorporationMedical devicesMid-sized10.3—15.4%
62OSANG HEALTHCARE CO.,LTD.Medical devicesMid-sized10.0-3.9%23.8%
63Aprogen, IncPharma & CDMOMid-sized9.9-67.4%13.7%
64Huvitz Co., Ltd.Medical devicesMid-sized9.8-8.5%17.3%
65Peptron, Inc.Biotech & drug discoverySME9.6+25.9%280.4%
66EuBiologics Co., Ltd.Biotech & drug discoverySME9.5+46.7%19.4%
67Hana Pharm. Co., Ltd.Pharma & CDMOMid-sized9.5+14.8%7.7%
68LivsMed Inc.Medical devicesSME9.4—41.3%
69Hugel, Inc.Pharma & CDMOLarge8.7+21.2%3.4%
70AHN-GOOK PHARMACEUTICAL Co., Ltd.Pharma & CDMOMid-sized8.7-8.7%4.6%
71SillaJen, Inc.Biotech & drug discoverySME8.4+62.1%165.6%
72Celltrion Pharm Inc.Pharma & CDMOLarge8.4+20.0%3.0%
73BioNote, Inc.Medical devicesMid-sized8.3+17.0%12.1%
74DRTECH CorporationMedical devicesSME8.3+23.7%12.0%
75ValueAddedTechnologyCo.,Ltd.Medical devicesMid-sized8.1+39.3%6.1%
76WHANIN PHARM CO.,LTDPharma & CDMOMid-sized8.0-31.0%5.6%
77CJ BioscienceBiotech & drug discoveryLarge7.9-14.3%469.9%
78ISU Abxis Co., Ltd.Biotech & drug discoveryMid-sized7.7-2.8%31.7%
79KANGSTEM BIOTECH CO., LTD.Biotech & drug discoverySME7.6—527.3%
80QuadMedicine Inc.Pharma & CDMOSME7.5+2.8%—
81S.Biomedics Co., Ltd.Pharma & CDMOSME7.4+59.1%80.5%
82MYUNGIN PHARM.CO., LTDPharma & CDMOMid-sized7.4—5.0%
83KOLON LIFE SCIENCE Inc.Pharma & CDMOLarge7.2+4.4%7.2%
84AbClon Inc.Biotech & drug discoverySME7.1-4.8%334.5%
85KWANGDONG PHARMACEUTICAL CO.,LTDPharma & CDMOMid-sized7.0-2.4%1.4%
86STCUBEBiotech & drug discoverySME7.0+50.9%242.8%
87YUNGJIN PHARM. CO., LTDPharma & CDMOLarge6.8+15.8%5.4%
88SELVAS AI Inc.Medical AISME6.7+32.1%11.1%
89CKD Bio Corp.Pharma & CDMOMid-sized6.6+5.4%8.0%
90PharmGen Science, Inc.Pharma & CDMOMid-sized6.4—7.0%
91KolmarBNH Co., LtdHealthcare infrastructureMid-sized6.1+23.3%2.3%
92MedPacto, Inc.Biotech & drug discoverySME5.9—249.3%
93GENORAY Co., LTD.Medical devicesSME5.9-3.5%11.3%
94Genome&CompanyBiotech & drug discoverySME5.9-8.6%48.9%
95meerecompanyIncorporatedMedical devicesSME5.8-14.4%12.9%
96KyungdongPharmPharma & CDMOMid-sized5.7-8.6%5.7%
97InBody Co., Ltd.Medical devicesMid-sized5.6—3.9%
98TiumBio Co., Ltd.Biotech & drug discoverySME5.5+11.6%73.8%
99JETEMA Co.,Ltd.Medical devicesSME5.3-53.5%14.6%
100Humedix Co., Ltd.Pharma & CDMOMid-sized5.2+4.7%5.7%
101ENCell Co., Ltd.Pharma & CDMOSME5.1—433.8%
102Daehan Nupharm Co.,Ltd.Pharma & CDMOMid-sized4.9-28.2%4.4%
103SUHEUNG CO.,LTD.Biotech & drug discoveryMid-sized4.8+7.9%2.3%
104FutureChem Co., Ltd.Pharma & CDMOSME4.8+87.8%44.7%
105DAE HWA PHARM CO., LTDPharma & CDMOMid-sized4.7-11.0%6.0%
106WON TECH CO.,Ltd.Medical devicesMid-sized4.6—5.2%
107CUREXO, INC.Medical devicesMid-sized4.5-5.2%11.4%
108NEXTBIOMEDICAL Co., Ltd.Medical devicesSME4.5+15.6%49.2%
109Shaperon Inc.Biotech & drug discoverySME4.2-5.0%1,000%+
110NEUROPHET Inc.Medical AISME4.1—325.4%
111SEERS Co., Ltd.Medical AISME4.1+62.2%6.7%
112G2GBIO, Inc.Pharma & CDMOSME3.9+0.4%202.0%
113CMG Pharmaceutical Co., Ltd.Pharma & CDMOSME3.9-15.0%7.3%
114Kukje Pharma Co., Ltd.Pharma & CDMOMid-sized3.9—4.2%
115HLB PHARMACEUTICAL CO., LTD.Biotech & drug discoverySME3.8+33.9%3.0%
116curacle co., ltd.Biotech & drug discoverySME3.8—46.2%
117DENTIUMMedical devicesMid-sized3.8-15.1%3.3%
118Pharmicell Co.,Ltd.Biotech & drug discoverySME3.7+7.1%4.9%
119Daebonglsco.,LtdPharma & CDMOSME3.7+2.3%5.9%
120Cellid Co., Ltd.Biotech & drug discoverySME3.7-56.1%69.7%
121IMBiologics Corp.Biotech & drug discoverySME3.7—50.8%
122INFINITT Healthcare Co., Ltd.Medical AISME3.6-2.1%14.4%
123MEDIANA Co.,LTDMedical devicesSME3.6—9.6%
124KOREA ARLICO PHARM CO.,LTD.Medical devicesMid-sized3.5+50.1%3.7%
125ORGANOIDSCIENCES LTD.Biotech & drug discoverySME3.4+19.4%464.4%
126Sam-A Pharm. Co. LtdPharma & CDMOSME3.4+36.9%9.3%
127Synergy Innovation Co., Ltd.Medical devicesSME3.4—5.8%
128ARIBIOLABBiotech & drug discoverySME3.3-27.6%1,000%+
129CORESTEMCHEMON Inc.Pharma & CDMOSME3.3-33.5%33.4%
130Tego Science, Inc.Biotech & drug discoverySME3.2+85.7%99.5%
131Bio Solution Co.,Ltd.Biotech & drug discoverySME3.1-20.9%36.5%
132THERAGEN ETEX CO.,LTD.Pharma & CDMOMid-sized3.0—2.2%
133JW LIFESCIENCE CORPORATIONPharma & CDMOMid-sized3.0+3.3%2.6%
134Cellbion Co., LtdPharma & CDMOSME3.0+18.4%274.5%
135VUNO, Inc.Medical AISME3.0-0.7%24.4%
136Noul Co., Ltd.Medical devicesSME2.9-28.7%219.1%
137DEEPNOID Inc.Medical AISME2.9+32.5%173.3%
138QuantaMatrix IncorporatedMedical devicesSME2.8—202.2%
139NIBEC CO., LTD.Medical devicesSME2.8-41.2%24.3%
140Y-Biologics, IncBiotech & drug discoverySME2.7—149.5%
141L&C BIO Co., LtdPharma & CDMOSME2.7+35.7%4.8%
142SAMIL PHARMACEUTICAL CO.,LTDPharma & CDMOMid-sized2.6—2.6%
143KOMIPHARM INTERNATIONAL CO., LTD.Pharma & CDMOSME2.5+43.4%8.8%
144CG Invites Co., Ltd.Biotech & drug discoverySME2.5-30.8%28.2%
145Micro Digital Co., Ltd.Medical devicesSME2.5—67.2%
146HEM Pharma Inc.Healthcare infrastructureSME2.4+16.3%25.6%
147CELL BIOTECH CO ., LTDPharma & CDMOSME2.4-0.1%8.5%
148Amicogen, Inc.Biotech & drug discoverySME2.4-35.2%9.4%
149SyntekaBio,Inc.Medical AISME2.4+119.6%284.9%
150IT-CHEM Co., Ltd.Pharma & CDMOSME2.3—8.4%
151MYUNGMOON PHARM CO.,LTDPharma & CDMOMid-sized2.3+8.7%2.3%
152COSMO ROBOTICS CO., LtdMedical devicesSME2.3—91.7%
153METABIOMED.CO.,LTDMedical devicesSME2.3—4.5%
154iNtRON Biotechnology, Inc.Biotech & drug discoverySME2.3—58.2%
155Xcell Therapeutics Inc.Pharma & CDMOSME2.2+45.7%75.6%
156CAREGEN CO.,LTD.Biotech & drug discoverySME2.2+23.7%5.3%
157SELVAS Healthcare, Inc.Medical devicesSME2.2+11.5%14.7%
158SHINIL PHARMACEUTICAL CO., LTD.Pharma & CDMOSME2.2——
159Kolmar BioTech, Inc.Pharma & CDMOMid-sized2.1—9.7%
160MITECH CO.,LTD.Medical devicesSME2.1—5.8%
1613billion Inc.Biotech & drug discoverySME2.1—29.1%
162T&L Co., LTD.Medical devicesSME2.0+4.5%2.0%
163Optipharm.CO.,LTDMedical devicesMid-sized2.0-3.2%16.9%
164ANTEROGEN CO., LTD.Biotech & drug discoverySME2.0+13.0%46.4%
165REYON PHARMACEUTICAL CO., LTDPharma & CDMOMid-sized2.0+31.7%2.8%
166HLB PANAGENE Co., LTD.Medical devicesSME2.0-13.5%29.1%
167Eutilex Co.,Ltd.Biotech & drug discoverySME2.0—110.7%
168NanoenTek,Inc.Medical devicesSME1.9+3.5%8.5%
169HLB Genex, Inc.Pharma & CDMOSME1.9—14.9%
170SAMSUNG PHARMACEUTICAL.CO.,Ltd.Pharma & CDMOSME1.9+17.5%10.2%
171ASTERASYS Co., Ltd.Medical devicesSME1.9+35.7%10.0%
172BioPlus Co., LtdPharma & CDMOSME1.9+13.8%3.6%
173Corentec Co., Ltd.Medical devicesSME1.8+1.3%4.7%
174Binex Co., Ltd.Pharma & CDMOMid-sized1.8+183.7%2.4%
175DIO CorporationMedical devicesMid-sized1.7-31.8%4.1%
176KUKJEON Co.,LtdPharma & CDMOSME1.7+9.0%2.3%
177JW SHINYAK CORPORATIONBiotech & drug discoveryMid-sized1.7—4.0%
178CU MEDICAL SYSTEMS Inc.Medical devicesSME1.7+33.6%4.8%
179PROTIA INC.Medical devicesSME1.7+25.4%18.1%
180T&R Biofab Co., LtdBiotech & drug discoverySME1.6-27.3%9.0%
181DONGSUNG PHARMACEUTICAL CO.,LTDPharma & CDMOMid-sized1.6-10.4%4.0%
182Icure Pharmaceutical IncorporationHealthcare infrastructureSME1.6+10.0%2.3%
183Gencurix Inc.Medical devicesSME1.6—31.4%
184Aprogen Biologics Inc.Pharma & CDMOMid-sized1.6—6.9%
185JPI Healthcare Co., Ltd.Medical devicesSME1.6-23.1%6.9%
186Oncocross Co.,Ltd.Medical AISME1.6-12.9%—
187VIVOZON PHARMACEUTICAL CO., LTD.Pharma & CDMOSME1.5-24.7%5.6%
188Precision Biosensor Inc.Medical devicesSME1.5+0.7%11.3%
189Coreline Soft Co., LtdMedical AISME1.5-1.9%—
190Yuyu Pharma, Inc.Pharma & CDMOMid-sized1.4-35.3%2.7%
191ENZYCHEM LIFESCIENCES CORPORATIONBiotech & drug discoverySME1.4-26.7%3.7%
192GC Medical Science CorporationMedical devicesMid-sized1.4-19.5%2.8%
193MEKICS Co., LtdMedical devicesSME1.4—18.8%
194DongKook Life Science Co., Ltd.Medical devicesMid-sized1.4+22.8%2.4%
195Acryl Inc.Medical AISME1.4—11.4%
196Raphas Co., Ltd.Medical devicesSME1.4—9.5%
197SINSIN PHARMACEUTICAL Co., LTD.Pharma & CDMOSME1.3-9.1%2.1%
198SEOUL PHARMA CO.,LTDPharma & CDMOMid-sized1.3-7.7%5.6%
199Plasmapp Co., Ltd.Medical devicesSME1.3-23.5%23.2%
200CHOONG ANG VACCINE LABORATORYBiotech & drug discoverySME1.3-5.0%5.3%
201JIN YANG PHARMACEUTICAL. CO., LTDPharma & CDMOMid-sized1.3+11.1%2.0%
202GFC Life Science Co., Ltd.Biotech & drug discoverySME1.3+36.3%12.2%
203GENEMATRIX INC.Biotech & drug discoverySME1.3-13.8%23.4%
204AMINOLOGICS CO.,LTD.Pharma & CDMOSME1.2+13.7%8.9%
205Daejung Chemicals & Metals Co., LtdPharma & CDMOSME1.2+2.2%1.9%
206Dynamic solution Co.,Ltd.Medical devicesSME1.1-24.2%15.6%
207Pangen Biotech Inc.Biotech & drug discoverySME1.1+51.6%14.4%
208Helixmith Co., LtdBiotech & drug discoverySME1.1-32.5%81.0%
209KOREA PHARMA Co., Ltd.Pharma & CDMOSME1.1-22.6%2.2%
210KOREAN DRUG CO., LTD.Pharma & CDMOSME1.1+11.0%3.5%
211SEWOONMEDICAL CO,. LTD.Medical devicesSME1.0+215.8%3.1%
212KYUNG NAM PHARM.CO.,LTD.Pharma & CDMOSME1.0-3.8%3.1%
213Autech CorporationMedical devicesMid-sized0.9+35.6%2.1%
214EOFlow Co., Ltd.Medical devicesSME0.8—373.2%
215BITComputerMedical AISME0.8+11.5%4.2%
216L&K BIOMED CO., LTD.Medical devicesSME0.8—10.3%
217P&K Skin Research Center Co.,Ltd.Biotech & drug discoverySME0.8+2.5%6.2%
218DongBang Medical Co., Ltd.Medical devicesSME0.8-46.7%1.2%
219RecensMedical, Inc.Medical devicesSME0.8—28.5%
220DaehanPharmaceuticalPharma & CDMOMid-sized0.7-40.0%0.6%
221ILSUNG IS CO., LTD.Pharma & CDMOSME0.7+30.5%2.0%
222POONGJEON PHARMACY CO.,LTD.Biotech & drug discoverySME0.7-56.1%2.4%
223WooGeneB&GCO.,LtdPharma & CDMOSME0.6+11.8%3.9%
224DAIHAN SCIENTIFIC CO., LtdHealthcare infrastructureSME0.6+18.9%1.5%
225Alpha AI Co.,Ltd.Medical devicesSME0.5+17.8%7.9%
226DreamCIS INC.Healthcare infrastructureMid-sized0.5-5.5%1.4%
227HLB bioStep Co.,Ltd.Biotech & drug discoverySME0.5-23.2%1.7%
228MOA Life Plus Co. Ltd.Biotech & drug discoverySME0.5+116.3%10.4%
229MEZOO Co., Ltd.Medical devicesSME0.5—4.9%
230BIOBIJOU Co., Ltd.Biotech & drug discoveryMid-sized0.5+33.1%2.6%
231LabGenomics. Co., Ltd.Medical devicesSME0.5-55.3%1.4%
232ChoA Pharmaceutical Co., LTD.Pharma & CDMOSME0.5-31.3%1.5%
233SHINHUNG CO.,LTDMedical devicesMid-sized0.4-13.6%0.8%
234UNION KOREA PHARM CO.,LtdPharma & CDMOSME0.4-17.5%3.2%
235TELCON RF PHARMACEUTICAL. Inc.Pharma & CDMOSME0.4-5.0%0.9%
236HIGH TECH PHARM CO.,LTD.Pharma & CDMOMid-sized0.4+44.1%0.9%
237BLUEMTEC CO., LTD.Healthcare infrastructureSME0.3-55.6%0.3%
238HWAIL PHARM. CO., LTDPharma & CDMOMid-sized0.3—0.7%
239SLSBio(Specialty Lab Solution Bio) Co., LtdBiotech & drug discoverySME0.3+0.3%14.7%
240GeneOne Life Science, Inc.Pharma & CDMOSME0.3-67.2%6.9%
241HUMASIS CO., LTD.Medical devicesSME0.3-29.2%1.8%
242C&R Research Inc.Healthcare infrastructureSME0.3-75.2%1.0%
243Daesung Microbiological Labs. Co. LtdPharma & CDMOSME0.3+36.2%2.7%
244TDSPHARM Co., Ltd.Pharma & CDMOSME0.3-9.6%1.9%
245Finemedix Co., Ltd.Medical devicesSME0.3-19.9%4.3%
246SCL Science Inc.Medical devicesSME0.3—1.7%
247IVIM Technology, Inc.Pharma & CDMOSME0.2-38.7%8.1%
248GREEN LIFESCIENCE CO., LTD.Pharma & CDMOSME0.2-31.6%0.6%
249CTC BIO, INC.Pharma & CDMOMid-sized0.2-65.7%0.3%
250RollingStone Co., Ltd.Medical devicesSME0.2—0.3%
251JMT CO.,Ltd.Medical devicesSME0.1-32.9%0.1%
252NATURECELL CO.,LTD.Pharma & CDMOSME0.1+38.2%0.6%
RankCompanyTwo-year R&D (KRW bn)Approvals (n)Korean trials (n)Global trials (n)Papers (n)Patents (n)
1Celltrion, Inc.902.42018133646
2LigaChem Biosciences Inc.330.4001333
3Hanmi Pharm. Co., Ltd.438.82391272114
4SK Bioscience Co.,Ltd262.00211640
5YUHAN CORPORATION511.2319262755
6DAEWOONG PHARMA454.55017212787
7Chong Kun Dang Pharmaceutical Corp.343.2551622775
8SAMSUNG EPIS HOLDINGS Co., Ltd.419.213022210
9SK biopharmaceuticals Co., Ltd.335.6001329
10GC Biopharma Corp.346.636531427
11SAMSUNG BIOLOGICS CO.,LTD.309.0000321
12DONG-A ST CO.,LTD251.61710161235
13ABL Bio Inc.167.5011820
14Kolon TissueGene, Inc.222.700005
15MEDIPOSTCO.,LTD.129.300051
16JW PHARMACEUTICAL191.2181210051
17SD BIOSENSOR INC.166.06600445
18HK inno.N Corporation163.11057634
19Voronoi, Inc.76.5003445
20JEIL PHARMACEUTICAL CO.,LTD86.52113026
21Orum Therapeutics, Inc.85.7000012
22Boryung Corporation124.731222723
23SEEGENE, INC.135.640068115
24Aimed Bio Inc.38.7000014
25IL DONG PHARMACEUTICAL CO., LTD.46.03121055
26PharmaResearch Co., Ltd.57.4702110
27DAEWON PHARMACEUTICAL CO.,LTD101.137187311
28Medy-Tox Inc.86.61001213
29SAM CHUN DANG PHARM CO. LTD36.581016
30HLB Co.,LTD.101.210008
31HUONS CO., LTD.76.741125117
32GI Innovation Inc.68.7011527
33i-SENS, Inc.64.12800199
34OliX Pharmaceuticals, Inc.47.2001314
35KOREA UNITED PHARM INC67.19114415
36ILYANG PHARMACEUTICAL CO.,LTD57.9327842
37DongKookPharmaceuticalCo.,Ltd.60.6613138
38Qurient Co., Ltd.43.300158
39SAMJIN PHARMACEUTICAL CO.,LTD71.02620218
40Mezzion Pharma Co., Ltd.37.701001
41KYONGBO PHARMACEUTICAL CO., LTD.38.61960216
42OSCOTECInc.49.1011012
43BUKWANG PHARMACEUTICAL IND CO.,LTD54.650000
44CLASSYS Inc.39.1704372
45Lunit Inc.72.41016460
46HANALL BIOPHARMA CO.,LTD69.031209
47ST PHARM CO., LTD.45.8000843
48Rznomics Inc.26.101227
49GC CELL CORPORATION51.7013420
50D&D Pharmatech Inc.48.300039
51Genexine, Inc.49.1012714
52Inventage Lab Inc.37.7001452
53Vieworks Co., Ltd.52.5800175
54Curocell Inc.64.601006
55DONGWHA PHARM.CO.,LTD49.9300017
56Boditech Med Inc.37.86300355
57BIONEERCORPORATION41.23101410
58HANDOK Inc.49.574334
59SHINPOONG PHARMACEUTICAL CO.,LTD30.6182004
60Chabiotech Co.,Ltd.42.3311010
61Samyang Biopharm Corporation——————
62OSANG HEALTHCARE CO.,LTD.41.03100011
63Aprogen, Inc110.700002
64Huvitz Co., Ltd.42.6300384
65Peptron, Inc.29.210028
66EuBiologics Co., Ltd.28.513292
67Hana Pharm. Co., Ltd.29.3205014
68LivsMed Inc.24.916002102
69Hugel, Inc.30.0102211
70AHN-GOOK PHARMACEUTICAL Co., Ltd.40.2115604
71SillaJen, Inc.30.2000312
72Celltrion Pharm Inc.33.8190011
73BioNote, Inc.30.800020
74DRTECH Corporation33.02200241
75ValueAddedTechnologyCo.,Ltd.28.8900035
76WHANIN PHARM CO.,LTD46.8214005
77CJ Bioscience40.9000202
78ISU Abxis Co., Ltd.29.701034
79KANGSTEM BIOTECH CO., LTD.26.7010629
80QuadMedicine Inc.29.900175
81S.Biomedics Co., Ltd.17.200083
82MYUNGIN PHARM.CO., LTD28.6152000
83KOLON LIFE SCIENCE Inc.15.600004
84AbClon Inc.27.8000114
85KWANGDONG PHARMACEUTICAL CO.,LTD30.41200413
86STCUBE24.302210
87YUNGJIN PHARM. CO., LTD25.593012
88SELVAS AI Inc.20.500006
89CKD Bio Corp.26.7200219
90PharmGen Science, Inc.28.590007
91KolmarBNH Co., Ltd24.3000126
92MedPacto, Inc.30.100078
93GENORAY Co., LTD.23.070003
94Genome&Company26.90011011
95meerecompanyIncorporated28.3100030
96KyungdongPharm24.6232001
97InBody Co., Ltd.24.1600116
98TiumBio Co., Ltd.21.300014
99JETEMA Co.,Ltd.39.5802215
100Humedix Co., Ltd.18.671112
101ENCell Co., Ltd.17.10121223
102Daehan Nupharm Co.,Ltd.16.8113005
103SUHEUNG CO.,LTD.17.32200313
104FutureChem Co., Ltd.15.102042
105DAE HWA PHARM CO., LTD23.5111005
106WON TECH CO.,Ltd.14.92300315
107CUREXO, INC.19.9100170
108NEXTBIOMEDICAL Co., Ltd.14.840015
109Shaperon Inc.19.70111117
110NEUROPHET Inc.12.7602309
111SEERS Co., Ltd.11.02011133
112G2GBIO, Inc.15.8002243
113CMG Pharmaceutical Co., Ltd.17.65211213
114Kukje Pharma Co., Ltd.11.2100201
115HLB PHARMACEUTICAL CO., LTD.11.4111004
116curacle co., ltd.20.400143
117DENTIUM16.8000049
118Pharmicell Co.,Ltd.14.601138
119Daebonglsco.,Ltd13.2000125
120Cellid Co., Ltd.32.80101029
121IMBiologics Corp.11.8000010
122INFINITT Healthcare Co., Ltd.17.430113
123MEDIANA Co.,LTD9.5200315
124KOREA ARLICO PHARM CO.,LTD.10.1303103
125ORGANOIDSCIENCES LTD.11.00001318
126Sam-A Pharm. Co. Ltd11.621004
127Synergy Innovation Co., Ltd.——————
128ARIBIOLAB19.001000
129CORESTEMCHEMON Inc.20.90101319
130Tego Science, Inc.8.511212
131Bio Solution Co.,Ltd.14.3000011
132THERAGEN ETEX CO.,LTD.10.41010020
133JW LIFESCIENCE CORPORATION11.110002
134Cellbion Co., Ltd12.321123
135VUNO, Inc.11.214012244
136Noul Co., Ltd.18.8000518
137DEEPNOID Inc.12.33001424
138QuantaMatrix Incorporated10.000023
139NIBEC CO., LTD.14.7102320
140Y-Biologics, Inc15.3000113
141L&C BIO Co., Ltd8.330245
142SAMIL PHARMACEUTICAL CO.,LTD14.160011
143KOMIPHARM INTERNATIONAL CO., LTD.7.100062
144CG Invites Co., Ltd.15.900016
145Micro Digital Co., Ltd.5.4100012
146HEM Pharma Inc.7.10011032
147CELL BIOTECH CO ., LTD9.00101012
148Amicogen, Inc.21.8000519
149SyntekaBio,Inc.5.2000227
150IT-CHEM Co., Ltd.11.100002
151MYUNGMOON PHARM CO.,LTD——————
152COSMO ROBOTICS CO., Ltd9.6302022
153METABIOMED.CO.,LTD10.0100003
154iNtRON Biotechnology, Inc.8.1000019
155Xcell Therapeutics Inc.8.400006
156CAREGEN CO.,LTD.13.1000270
157SELVAS Healthcare, Inc.7.450012
158SHINIL PHARMACEUTICAL CO., LTD.8.6200001
159Kolmar BioTech, Inc.11.400001
160MITECH CO.,LTD.7.7100001
1613billion Inc.7.70006413
162T&L Co., LTD.10.300039
163Optipharm.CO.,LTD8.91002712
164ANTEROGEN CO., LTD.7.210103
165REYON PHARMACEUTICAL CO., LTD7.762001
166HLB PANAGENE Co., LTD.8.740000
167Eutilex Co.,Ltd.24.100018
168NanoenTek,Inc.8.120004
169HLB Genex, Inc.17.400009
170SAMSUNG PHARMACEUTICAL.CO.,Ltd.5.550000
171ASTERASYS Co., Ltd.5.940004
172BioPlus Co., Ltd6.310002
173Corentec Co., Ltd.8.1800823
174Binex Co., Ltd.2.490002
175DIO Corporation9.31800013
176KUKJEON Co.,Ltd6.600016
177JW SHINYAK CORPORATION6.640000
178CU MEDICAL SYSTEMS Inc.4.910001
179PROTIA INC.5.360004
180T&R Biofab Co., Ltd10.01300735
181DONGSUNG PHARMACEUTICAL CO.,LTD8.3141002
182Icure Pharmaceutical Incorporation6.1700019
183Gencurix Inc.8.710044
184Aprogen Biologics Inc.23.7185000
185JPI Healthcare Co., Ltd.9.3100115
186Oncocross Co.,Ltd.6.300087
187VIVOZON PHARMACEUTICAL CO., LTD.6.981000
188Precision Biosensor Inc.6.2200027
189Coreline Soft Co., Ltd6.116001622
190Yuyu Pharma, Inc.8.2150012
191ENZYCHEM LIFESCIENCES CORPORATION8.001034
192GC Medical Science Corporation6.6100001
193MEKICS Co., Ltd5.890004
194DongKook Life Science Co., Ltd.4.8110000
195Acryl Inc.3.1600126
196Raphas Co., Ltd.4.00001118
197SINSIN PHARMACEUTICAL Co., LTD.5.3242004
198SEOUL PHARMA CO.,LTD5.481000
199Plasmapp Co., Ltd.7.7500629
200CHOONG ANG VACCINE LABORATORY5.700014
201JIN YANG PHARMACEUTICAL. CO., LTD4.3136002
202GFC Life Science Co., Ltd.3.6200646
203GENEMATRIX INC.6.121014
204AMINOLOGICS CO.,LTD.4.100003
205Daejung Chemicals & Metals Co., Ltd——————
206Dynamic solution Co.,Ltd.6.820007
207Pangen Biotech Inc.3.400013
208Helixmith Co., Ltd11.6000313
209KOREA PHARMA Co., Ltd.4.8142011
210KOREAN DRUG CO., LTD.4.260012
211SEWOONMEDICAL CO,. LTD.2.120000
212KYUNG NAM PHARM.CO.,LTD.4.2220001
213Autech Corporation3.400002
214EOFlow Co., Ltd.2.9100074
215BITComputer——————
216L&K BIOMED CO., LTD.2.8110003
217P&K Skin Research Center Co.,Ltd.3.300031
218DongBang Medical Co., Ltd.5.9240004
219RecensMedical, Inc.5.9500255
220DaehanPharmaceutical4.010000
221ILSUNG IS CO., LTD.2.690000
222POONGJEON PHARMACY CO.,LTD.9.500005
223WooGeneB&GCO.,Ltd2.600085
224DAIHAN SCIENTIFIC CO., Ltd2.220000
225Alpha AI Co.,Ltd.2.020006
226DreamCIS INC.2.4171012
227HLB bioStep Co.,Ltd.2.500031
228MOA Life Plus Co. Ltd.1.400013
229MEZOO Co., Ltd.1.620195
230BIOBIJOU Co., Ltd.2.1700010
231LabGenomics. Co., Ltd.4.6100021
232ChoA Pharmaceutical Co., LTD.3.2130005
233SHINHUNG CO.,LTD1.6270000
234UNION KOREA PHARM CO.,Ltd2.260001
235TELCON RF PHARMACEUTICAL. Inc.1.410000
236HIGH TECH PHARM CO.,LTD.1.400010
237BLUEMTEC CO., LTD.——————
238HWAIL PHARM. CO., LTD1.500003
239SLSBio(Specialty Lab Solution Bio) Co., Ltd——————
240GeneOne Life Science, Inc.5.500031
241HUMASIS CO., LTD.2.230000
242C&R Research Inc.6.302004
243Daesung Microbiological Labs. Co. Ltd——————
244TDSPHARM Co., Ltd.1.320001
245Finemedix Co., Ltd.1.11200014
246SCL Science Inc.4.1300115
247IVIM Technology, Inc.1.600045
248GREEN LIFESCIENCE CO., LTD.——————
249CTC BIO, INC.3.070004
250RollingStone Co., Ltd.4.100003
251JMT CO.,Ltd.0.660003
252NATURECELL CO.,LTD.0.401001
·Alteogen Inc.116.1100218
·Ensol Biosciences Inc.8.110019
·Femtobiomed Inc.3.200003
·Future Medicine Co., Ltd.6.7000199
·Hancom Lifecare Inc.4.6000010
·MEDYSSEY CO.,LTD2.040004
·Moogene Medi Co., Ltd.2.8010212
·NovMetaPharma Co., Ltd.5.1000339
·ProGen, Co,, LTD.29.301222
·UXN Co., Ltd.7.6000015

Two-year R&D and output cover 2024–2025 (patents: 2023–2024 filings). "·" rows have two-year values but no H1 2026 value and are included in two-year totals. "—" marks companies without both years, or with no disclosed output, which are not named (IV-5).

© 2026 Medical AI Alliance. This report and its company data are licensed under the Creative Commons Attribution 4.0 International licence (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/): free to share and adapt, including commercially, with attribution to Medical AI Alliance (MAA) and an indication of any changes.

How to cite · Medical AI Alliance (2026), "R&D Investment and Output, Korea's Listed Healthcare Sector — H1 2026", MAA Report, https://medicalaialliance.org/en/reports/rnd-invest-2026h1 (full edition 2026-10-07)